ASCO 2013 - Poster: Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

CHICAGO, IL USA ( - Presented by N.J. Vogelzang,1 S.I. Helle,,2 D.C. Johannessen,3 J.M. O’Sullivan,4 J. Garcia-Vargas,5 C.G. O’Bryan-Tear,6 M. Shan,5 and C. Parker7 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA


asco 2013 vogelzang poster thumb

1Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; 2Haukeland University Hospital, Bergen, Norway; 3Ullevål University Hospital, Oslo, Norway; 4Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, Ireland; 5Bayer HealthCare, Montville, NJ, USA; 6Algeta ASA, Oslo, Norway; 7The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK

Click HERE to listen to a podcast by Nicholas Vogelzang, MD, one of the participants in this study.


The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage